510(k) · Cleared
ClearedCureSight-CS100
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Novasight, Ltd. · QQU Digital Therapy Device For Amblyopia
Cleared on Sep 29, 2022 as substantially equivalent to DEN210005 (Luminopia, Inc., 2021) after a 140-day review. Its family tree reaches back 1 generation to 2021.
- Decided
- Sep 29, 2022
- Review
- 140 days
- Class
- Class II
- Product code
- QQU
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 1 generation to DEN210005 (2021). No later device cites it as a predicate yet.
- Root · 1 generation backDEN210005 Luminopia OneLuminopia, Inc. · 2021
- This deviceK221375 CureSight-CS100Novasight, Ltd. · 2022
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | DEN210005 | Luminopia One | Luminopia, Inc. | 2021 | — |
| 0 (this device) | K221375 | CureSight-CS100 | Novasight, Ltd. | 2022 | — |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in QQU? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new QQU device
- #1 K233720 Luminopiascore 11.1 · 2 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | DEN210005 | Luminopia OneSummary page 4…886.5500, Class II CODE QQU PREDICATE DEVICE: Luminopia One DEN210005 (October 20, 2021) DEVICE DESCRIPTION The CureSight™ system is an eye-tracking-based system aimed for improving visual acuity an… | 2021 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Its one ancestor has no recall.
- 1 other device also cites its predicate DEN210005.
How does its category compare?
All QQU devicesQQU Digital Therapy Device For Amblyopia: FDA decisions, review times, recalls and adverse event reports over 20 years. 2022, this device’s year, is highlighted.
FDA decisions per year · QQU
1in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · QQU
Too few QQU 510(k)s in any year since 2007 to give a median.
Recalls per year · QQU
No recall names QQU since 2007.
Adverse event reports per year · QQU
1in 2025
MAUDE reports naming product code QQU, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 0 | — | 0 | 0 |
| 2019 | 0 | — | 0 | 0 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 1 | — | 0 | 0 |
| 2022 | 2 | — | 0 | 0 |
| 2023 | 0 | — | 0 | 0 |
| 2024 | 1 | — | 0 | 0 |
| 2025 | 1 | — | 0 | 1 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The CureSight™ system is indicated for improvement in visual acuity and stereo acuity in amblyopia patients, aged 4 - <9 years, associated with anisometropia and/or with mild strabismus, having received treatment instructions (frequency and duration) as prescribed by a trained eye-care professional. CureSight™ is intended for both previously treated and untreated patients and is intended to be used as an adjunct to full-time refractive correction, such as glasses, which should also be worn under the anaglyph glasses during CureSight™ treatment. CureSight™ is intended for prescription use only, in an at-home environment.
Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K221375 · printed Nov 6, 2026
Cite this page
510(k) Report. “K221375: CureSight-CS100.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K221375
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026